| Literature DB >> 28149156 |
M Alkhorayef1, E Babikir1, A Alrushoud2, H Al-Mohammed3, A Sulieman4.
Abstract
Computed tomography angiography (CTA) has become the most valuable imaging modality for the diagnosis of blood vessel diseases; however, patients are exposed to high radiation doses and the probability of cancer and other biological effects is increased. The objectives of this study were to measure the patient radiation dose during a CTA procedure and to estimate the radiation dose and biological effects. The study was conducted in two radiology departments equipped with 64-slice CT machines (Aquilion) calibrated according to international protocols. A total of 152 patients underwent brain, lower limb, chest, abdomen, and pelvis examinations. The effective radiation dose was estimated using ImPACT scan software. Cancer and biological risks were estimated using the International Commission on Radiological Protection (ICRP) conversion factors. The mean patient dose value per procedure (dose length product [DLP], mGy·cm) for all examinations was 437.8 ± 166, 568.8 ± 194, 516.0 ± 228, 581.8 ± 175, and 1082.9 ± 290 for the lower limbs, pelvis, abdomen, chest, and cerebral, respectively. The lens of the eye, uterus, and ovaries received high radiation doses compared to thyroid and testis. The overall patient risk per CTA procedure ranged between 15 and 36 cancer risks per 1 million procedures. Patient risk from CTA procedures is high during neck and abdomen procedures. Special concern should be provided to the lens of the eye and thyroid during brain CTA procedures. Patient dose reduction is an important consideration; thus, staff should optimize the radiation dose during CTA procedures.Entities:
Keywords: CTA; Computed tomography; Effective dose; Medical exposure; Radiation risk
Year: 2016 PMID: 28149156 PMCID: PMC5272934 DOI: 10.1016/j.sjbs.2016.01.011
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.219
Patient data distribution according to gender for angiographic procedures.
| Gender | Limbs | Abdomen | Chest | Head | Pelvis | Total | Percentage (%) |
|---|---|---|---|---|---|---|---|
| Male | 31 | 15 | 15 | 12 | 11 | 84 | 55.3 |
| Female | 14 | 9 | 11 | 11 | 23 | 68 | 44.7 |
| Total | 45 | 44 | 26 | 23 | 34 | 152 | 100 |
Show image acquisition parameters according to gender.
| Gender | Age (year) | Total time (s) | Tube voltage | Tube current (mA) | Pitch |
|---|---|---|---|---|---|
| Male | 51.4 ± 19.41 | 61.99 ± 21.43 | 120 | 150 ± 70 | 0.92 |
| Female | 59.7 ± 20.70 | 56.78 ± 21.45 | 120 | 150 ± 70 | 0.92 |
Constant potential.
Patients’ doses during CTA procedures.
| Procedure | CTDIvol (mGy) | DLP (mGy·cm) | Effective dose (mSv) |
|---|---|---|---|
| Cerebral | 70.8 ± 4 | 1082.9 ± 290 | 2.3 ± 0.6 |
| Chest | 30.5 ± 13 | 581.8 ± 175 | 8.1 ± 2.6 |
| Abdomen | 37.7 ± 16 | 516.0 ± 228 | 7.4 ± 3.4 |
| Pelvis | 27.2 ± 10.0 | 568.8 ± 194 | 8.9 ± 3 |
| Lower limbs | 14.7 ± 8 | 437.8 ± 166 | 3.9 ± 1.4 |
Organ dose equivalent for certain radiosensitive organs during CTA procedure.
| CT procedure | Organ equivalent dose (mSv) | |||||
|---|---|---|---|---|---|---|
| Eye lens | Thyroid | Breast | Uterus | Ovaries | Testis | |
| Cerebral | 41.2 | 2.2 | 0.03 | 0 | 0 | 0 |
| Chest | 0.1 | 1.4 | 13.3 | 0.04 | 0.05 | 0 |
| Abdomen | 0 | 0.05 | 0.6 | 7.4 | 7.5 | 0.6 |
| Pelvis | 0 | 0 | 0.02 | 24 | 23 | 1.6 |
Patient organ dose and risk estimation per gender and procedure type.
| CTA procedure | Organ | Organ equivalent dose (mSv) | Risk coefficient 10−4 | Cancer probability 10−6 |
|---|---|---|---|---|
| Cerebral | Thyroid | 2.2 | 33 | 73 |
| Chest | Breast | 12.3 | 112 | 1377 |
| Abdomen | Uterus | 24 | 143 | 3432 |
| Pelvis | Ovaries | 23 | 11 | 253 |
| Pelvis | Testis | 1.6 | 20 | 32 |
| Overall cancer risk per procedure |
Hereditary.
Overall cancer risk per procedure.
| CTA procedure | Mean effective dose (10−3 Sv) | Risk coefficient (S v−1) | Cancer probability 10−5 |
|---|---|---|---|
| Cerebral | 2.3 | 5.5 × 10−2 | 13 |
| Chest | 8.1 | 45 | |
| Abdomen | 7.4 | 41 | |
| Pelvis | 8.9 | 49 |